Literature DB >> 23640609

Correlation of transient vision loss with outer retinal disruption following intravitreal ocriplasmin.

K B Freund, S A Shah, V P Shah.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23640609      PMCID： PMC3682374          DOI： 10.1038/eye.2013.94

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN： 0950-222X            Impact factor:   3.775


× No keyword cloud information.
  1 in total

1.  Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes.

Authors:  Peter Stalmans; Matthew S Benz; Arnd Gandorfer; Anselm Kampik; Aniz Girach; Stephen Pakola; Julia A Haller
Journal:  N Engl J Med       Date:  2012-08-16       Impact factor: 91.245
  1 in total
  24 in total

1.  [Ocriplasmin as a treatment option for symptomatic vitreomacular traction with and without macular hole. First clinical experiences].

Authors:  M Maier; S Abraham; C Frank; N Feucht; C P Lohmann
Journal:  Ophthalmologe       Date:  2015-12       Impact factor: 1.059

2.  [Unclear retinopathy after intravitreal injection of ocriplasmin].

Authors:  S Abraham; K Wand; S Stumpfe; N Feucht; C P Lohmann; M Maier
Journal:  Ophthalmologe       Date:  2016-02       Impact factor: 1.059

3.  Acute ocriplasmin retinopathy.

Authors:  Mark W Johnson; Abigail T Fahim; Rajesh C Rao
Journal:  Retina       Date:  2015-06       Impact factor: 4.256

4.  [Pharmaological vitreolysis with ocriplasmin as a treatment option for symptomatic focal vitreomacular traction with or without macular holes (≤400 μm) compared to tranconjunctival vitrectomy].

Authors:  M Maier; S Abraham; C Frank; C P Lohmann; N Feucht
Journal:  Ophthalmologe       Date:  2017-02       Impact factor: 1.059

5.  Real-life experience after intravitreal ocriplasmin for vitreomacular traction and macular hole: a spectral-domain optical coherence tomography prospective study.

Authors:  Irini Chatziralli; George Theodossiadis; Efstratios Parikakis; Ioannis Datseris; Panagiotis Theodossiadis
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-05-05       Impact factor: 3.117

Review 6.  Ocriplasmin use for vitreomacular traction and macular hole: A meta-analysis and comprehensive review on predictive factors for vitreous release and potential complications.

Authors:  Irini Chatziralli; George Theodossiadis; Paraskevi Xanthopoulou; Michael Miligkos; Sobha Sivaprasad; Panagiotis Theodossiadis
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-04-30       Impact factor: 3.117

7.  ELLIPSOID ZONE MAPPING AND OUTER RETINAL CHARACTERIZATION AFTER INTRAVITREAL OCRIPLASMIN.

Authors:  Yuji Itoh; Justis P Ehlers
Journal:  Retina       Date:  2016-12       Impact factor: 4.256

8.  Ocriplasmin for treatment of stage 2 macular holes: early clinical results.

Authors:  John B Miller; Leo A Kim; David M Wu; Demetrios G Vavvas; Dean Eliott; Deeba Husain
Journal:  Ophthalmic Surg Lasers Imaging Retina       Date:  2014 Jul-Aug       Impact factor: 1.300

Review 9.  Assessment of retinal alterations after intravitreal ocriplasmin with spectral-domain optical coherence tomography.

Authors:  Yuji Itoh; Peter K Kaiser; Rishi P Singh; Sunil K Srivastava; Justis P Ehlers
Journal:  Ophthalmology       Date:  2014-09-07       Impact factor: 12.079

10.  Utility of intraoperative optical coherence tomography during vitrectomy surgery for vitreomacular traction syndrome.

Authors:  Justis P Ehlers; Tiffany Tam; Peter K Kaiser; Daniel F Martin; Gina M Smith; Sunil K Srivastava
Journal:  Retina       Date:  2014-07       Impact factor: 4.256
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.